Company Overview and News
President Trump announced this week that the White House is in the process of implementing a rules change that will allow E15 to sold year-round in the U.S.
ANDE GPRE PEIX VLO MPC DK HFC REX GPP CVRR REGI ADM FF
CVR Refining (NYSE:CVRR) is a master limited partnership that has had a controversial history given its majority ownership by Carl Icahn. Along with the rest of the oil industry in general, and the refining industry in particular, CVRR had huge problems from the end of 2015 through the early part of last year. Crack spreads (the difference between the price of crude oil input and the price of products sold which are mostly gasoline and diesel) collapsed to the point where they were losing a lot of money.
2018-10-11 seekingalpha - 1
Energy equities with over .05% Broker Target Upsides showed midstream firms top on the list, Sanchez for price gains and American Midstream for dividend yield, as of 10/8/18.
NGL AMID SNP MMLP SMLP BPL CCLP ETP SNP USAC GPP CVRR SNMP
SUGAR LAND, Texas, Sept. 17, 2018 (GLOBE NEWSWIRE) -- CVR Refining, LP (NYSE: CVRR), a refiner and marketer of petroleum fuels, today announced that it intends to sell its Cushing, Oklahoma, crude oil tank farm and currently is entertaining bids from potential purchasers. The 1.5-million-barrel crude oil storage facility sits on approximately 130 acres and includes six storage tanks, each with the capacity to hold 250,000 barrels of crude oil.
2018-09-07 seekingalpha - 1
Energy equities with over .72% Broker Target Upsides showed midstream firms tops on the list, Sanchez, for price upside and American Midstream for net gains, and yield as of 9/6/18.
NGL AMID SNP MMLP SMLP BPL CCLP ETP SNP USAC GPP CVRR ENBL SNMP
2018-09-03 seekingalpha - 6
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
VLTCP CQP CVI SDRPQ FCX TPCA VMW ENZN AFNL HRI NWL EGN VLTCW CI WBT VKSC ARII LNG GLPI SD XRX IEP NAV CNDT SDOCQ HLF UAN DVMT ERI CVRR VLTC MTW SDRXP HTZ SDRXQ
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#(O2VED7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E M'0O26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R P M(# @-C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T M4&%R96YT
For context, 2Q18 distributions refer to the distributions that will be paid in 3Q18 as a result of operational performance in 2Q18. The pie charts below reflect the Q/Q changes to distributions, comparing 2Q18 with 1Q18. For this exercise, we included Williams Partners (former ticker WPZ), which declared a distribution on July 23rd with a record date of August 3rd and was subsequently removed from both indices due to its merger with Williams Companies Inc.
BKEP AMID RMP EPD ALJ SEP ANDX HCLP AM GNE EQM WPZ WMB MMP PAA GEL MPLX VNOM PSXP TCP ALDW SHLX DM WES CVRR SPH GNE NS
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET